Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth

Jin Soo Kim; Dennis R. Taaffe; Daniel A. Galvão; Nicolas H. Hart; Elin Gray; Charles J. Ryan; Stacey A. Kenfield; Fred Saad; Robert U. Newton

doi:10.1038/s41391-022-00504-x

Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth

Jin Soo Kim, Dennis R. Taaffe, Daniel A. Galvão, Nicolas H. Hart, Elin Gray, Charles J. Ryan, Stacey A. Kenfield, Fred Saad, Robert U. Newton

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

Background: Altering the systemic milieu through exercise has been proposed as a potential mechanism underlying exercise-driven tumour suppression. It is not yet known whether men with advanced prostate cancer can elicit such adaptations following a program of exercise. The purpose is to examine myokine levels of serum acquired from metastatic castrate-resistant prostate cancer (mCRPC) patients recruited to the INTERVAL-GAP4 trial before and after 6 months of exercise and its tumour-suppressive effect. Methods: Twenty-five men with mCRPC (age = 74.7 ± 7.1 yrs) were randomised to supervised multimodal (aerobic and resistance) exercise (EX) or self-directed exercise control group (CON). Body composition was assessed using dual-energy x-ray absorptiometry (DXA), and fasting blood in a rested state was collected at baseline and at 6 months. Serum levels of myokines (SPARC, OSM, decorin, IGF-1, and IGFBP-3) were measured. Serum was applied to the prostate cancer cell line DU145, and growth was assessed for 72 h. Results: No significant change in body composition was observed. Adjusted serum OSM (P = 0.050) and relative OSM (P = 0.083), serum SPARC (P = 0.022) and relative SPARC (P = 0.025) increased in EX compared to CON. The area under curve (AUC) over 72 h showed a significant reduction in DU145 growth after applying post-intervention serum from the EX vs CON (P = 0.029). Conclusion: Elevated myokine expressions and greater tumour-suppressive effects of serum after 6 months of periodised and autoregulated supervised exercise was observed in men with mCRPC. Exercise-induced systemic changes may slow disease progression in men with advanced prostate cancer.

Original language	English (US)
Pages (from-to)	86-92
Number of pages	7
Journal	Prostate Cancer and Prostatic Diseases
Volume	25
Issue number	1
DOIs	https://doi.org/10.1038/s41391-022-00504-x
State	Published - Mar 2022

Bibliographical note

Funding Information:
This work was funded by the Movember Foundation. National Health and Medical Research Council Centre of Research Excellence (NHMRC-CRE; APP1116334) funded the additional materials involving serum analysis and cell work through Centre for Research Excellence in Prostate Cancer Survivorship. J-S.K is supported by the NHMRC Centre for Research Excellence in Prostate Cancer Survivorship Scholarship. Open Access funding enabled and organized by CAUL and its Member Institutions.

Funding Information:
The authors thank Harry Perkins Institute, Nedlands, WA, Australia, for providing prostate cancer cell line DU145.

Publisher Copyright:
© 2022, The Author(s).

PubMed: MeSH publication types

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1038/s41391-022-00504-x

OpenUrl availability

Full text

Cite this

@article{67e8117da09547b3af07d3a33625bc07,

title = "Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth",

abstract = "Background: Altering the systemic milieu through exercise has been proposed as a potential mechanism underlying exercise-driven tumour suppression. It is not yet known whether men with advanced prostate cancer can elicit such adaptations following a program of exercise. The purpose is to examine myokine levels of serum acquired from metastatic castrate-resistant prostate cancer (mCRPC) patients recruited to the INTERVAL-GAP4 trial before and after 6 months of exercise and its tumour-suppressive effect. Methods: Twenty-five men with mCRPC (age = 74.7 ± 7.1 yrs) were randomised to supervised multimodal (aerobic and resistance) exercise (EX) or self-directed exercise control group (CON). Body composition was assessed using dual-energy x-ray absorptiometry (DXA), and fasting blood in a rested state was collected at baseline and at 6 months. Serum levels of myokines (SPARC, OSM, decorin, IGF-1, and IGFBP-3) were measured. Serum was applied to the prostate cancer cell line DU145, and growth was assessed for 72 h. Results: No significant change in body composition was observed. Adjusted serum OSM (P = 0.050) and relative OSM (P = 0.083), serum SPARC (P = 0.022) and relative SPARC (P = 0.025) increased in EX compared to CON. The area under curve (AUC) over 72 h showed a significant reduction in DU145 growth after applying post-intervention serum from the EX vs CON (P = 0.029). Conclusion: Elevated myokine expressions and greater tumour-suppressive effects of serum after 6 months of periodised and autoregulated supervised exercise was observed in men with mCRPC. Exercise-induced systemic changes may slow disease progression in men with advanced prostate cancer.",

author = "Kim, {Jin Soo} and Taaffe, {Dennis R.} and Galv{\~a}o, {Daniel A.} and Hart, {Nicolas H.} and Elin Gray and Ryan, {Charles J.} and Kenfield, {Stacey A.} and Fred Saad and Newton, {Robert U.}",

note = "Funding Information: This work was funded by the Movember Foundation. National Health and Medical Research Council Centre of Research Excellence (NHMRC-CRE; APP1116334) funded the additional materials involving serum analysis and cell work through Centre for Research Excellence in Prostate Cancer Survivorship. J-S.K is supported by the NHMRC Centre for Research Excellence in Prostate Cancer Survivorship Scholarship. Open Access funding enabled and organized by CAUL and its Member Institutions. Funding Information: The authors thank Harry Perkins Institute, Nedlands, WA, Australia, for providing prostate cancer cell line DU145. Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = mar,

doi = "10.1038/s41391-022-00504-x",

language = "English (US)",

volume = "25",

pages = "86--92",

journal = "Prostate Cancer and Prostatic Diseases",

issn = "1365-7852",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth

AU - Kim, Jin Soo

AU - Taaffe, Dennis R.

AU - Galvão, Daniel A.

AU - Hart, Nicolas H.

AU - Gray, Elin

AU - Ryan, Charles J.

AU - Kenfield, Stacey A.

AU - Saad, Fred

AU - Newton, Robert U.

N1 - Funding Information: This work was funded by the Movember Foundation. National Health and Medical Research Council Centre of Research Excellence (NHMRC-CRE; APP1116334) funded the additional materials involving serum analysis and cell work through Centre for Research Excellence in Prostate Cancer Survivorship. J-S.K is supported by the NHMRC Centre for Research Excellence in Prostate Cancer Survivorship Scholarship. Open Access funding enabled and organized by CAUL and its Member Institutions. Funding Information: The authors thank Harry Perkins Institute, Nedlands, WA, Australia, for providing prostate cancer cell line DU145. Publisher Copyright: © 2022, The Author(s).

PY - 2022/3

Y1 - 2022/3

N2 - Background: Altering the systemic milieu through exercise has been proposed as a potential mechanism underlying exercise-driven tumour suppression. It is not yet known whether men with advanced prostate cancer can elicit such adaptations following a program of exercise. The purpose is to examine myokine levels of serum acquired from metastatic castrate-resistant prostate cancer (mCRPC) patients recruited to the INTERVAL-GAP4 trial before and after 6 months of exercise and its tumour-suppressive effect. Methods: Twenty-five men with mCRPC (age = 74.7 ± 7.1 yrs) were randomised to supervised multimodal (aerobic and resistance) exercise (EX) or self-directed exercise control group (CON). Body composition was assessed using dual-energy x-ray absorptiometry (DXA), and fasting blood in a rested state was collected at baseline and at 6 months. Serum levels of myokines (SPARC, OSM, decorin, IGF-1, and IGFBP-3) were measured. Serum was applied to the prostate cancer cell line DU145, and growth was assessed for 72 h. Results: No significant change in body composition was observed. Adjusted serum OSM (P = 0.050) and relative OSM (P = 0.083), serum SPARC (P = 0.022) and relative SPARC (P = 0.025) increased in EX compared to CON. The area under curve (AUC) over 72 h showed a significant reduction in DU145 growth after applying post-intervention serum from the EX vs CON (P = 0.029). Conclusion: Elevated myokine expressions and greater tumour-suppressive effects of serum after 6 months of periodised and autoregulated supervised exercise was observed in men with mCRPC. Exercise-induced systemic changes may slow disease progression in men with advanced prostate cancer.

AB - Background: Altering the systemic milieu through exercise has been proposed as a potential mechanism underlying exercise-driven tumour suppression. It is not yet known whether men with advanced prostate cancer can elicit such adaptations following a program of exercise. The purpose is to examine myokine levels of serum acquired from metastatic castrate-resistant prostate cancer (mCRPC) patients recruited to the INTERVAL-GAP4 trial before and after 6 months of exercise and its tumour-suppressive effect. Methods: Twenty-five men with mCRPC (age = 74.7 ± 7.1 yrs) were randomised to supervised multimodal (aerobic and resistance) exercise (EX) or self-directed exercise control group (CON). Body composition was assessed using dual-energy x-ray absorptiometry (DXA), and fasting blood in a rested state was collected at baseline and at 6 months. Serum levels of myokines (SPARC, OSM, decorin, IGF-1, and IGFBP-3) were measured. Serum was applied to the prostate cancer cell line DU145, and growth was assessed for 72 h. Results: No significant change in body composition was observed. Adjusted serum OSM (P = 0.050) and relative OSM (P = 0.083), serum SPARC (P = 0.022) and relative SPARC (P = 0.025) increased in EX compared to CON. The area under curve (AUC) over 72 h showed a significant reduction in DU145 growth after applying post-intervention serum from the EX vs CON (P = 0.029). Conclusion: Elevated myokine expressions and greater tumour-suppressive effects of serum after 6 months of periodised and autoregulated supervised exercise was observed in men with mCRPC. Exercise-induced systemic changes may slow disease progression in men with advanced prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=85124386681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85124386681&partnerID=8YFLogxK

U2 - 10.1038/s41391-022-00504-x

DO - 10.1038/s41391-022-00504-x

M3 - Article

C2 - 35152272

AN - SCOPUS:85124386681

SN - 1365-7852

VL - 25

SP - 86

EP - 92

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

IS - 1

ER -

Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth

Abstract

Bibliographical note

PubMed: MeSH publication types

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this